《科创板日报》12月31日讯（记者 史士云）2025年，科创板医药板块展现出更具说服力的市场叙事能力，也获得了资本市场的更多垂青。 数据显示，截至2025年12月26日，科创板医药板块上市的企业共有118家，其中98家企业的股价实现了年内的整体上涨，仅有不到20家企业（剔除近期上市 的新股）股价下跌。 从上市情况看，2025年科创板医药板块新增上市企业5家，而2024年为1家，另有包括汉诺医疗、信诺维、同心医疗等企业的科创板IPO也于近日获得受理。 此外，2025年，科创板生物医药企业IPO终止数量也显著下降，全年仅有天星医疗1家企业终止审核。而2024年同类企业终止数量超过10家。 相较于2024年市场的清冷，2025年的科创板生物医药板暖意已显。 ▌政策加持，年内新增5家生物医药企业 2025年6月18日，是一个再平凡不过的周四，但对于科创板而言，却迎来了市场改革的重要节点。 在当日召开的"2025陆家嘴论坛"上，中国证监会主席吴清宣布，证监会将推出进一步深化科创板改革"1+6"政策措施，包括设置科创板科创成长层，且重启 未盈利企业适用科创板第五套上市标准，以及面向优质科技企业试点IPO预先审阅机制等。同 ...

来源：中国新闻网 编辑：熊思怡 广告等商务合作，请点击这里 本文为转载内容，授权事宜请联系原著作权人 广东流感达到流行高峰后现下降趋势 中新网广州12月25日电 (记者 蔡敏婕)广东省疾病预防控制中心25日发布消息称，今年第51周(12月15日 —21日)，广东省流感监测哨点医院的流感样病例占门急诊病例总数百分比为8.09%，低于上周水平 (10.56%)，高于基线水平(5.89%)；门急诊流感样病例标本流感病毒阳性检出率为46.69%，低于上周水 平(57.33%)，高于基线水平(12.44%)，以甲型H3N2为主；本周报告4起流感暴发疫情。 广东省疾控中心副主任、传染病防控首席专家康敏指出，广东自第37周进入流感流行季，目前达到流行 高峰后出现下降趋势，但整体仍处于较高水平。建议广大市民继续保持勤洗手、讲卫生的好习惯，注意 居室通风，减少前往人群密集或通风不佳的公共场所，如需前往建议佩戴口罩。 暴发疫情起数逐步减少，集中在中小学。康敏建议学校、托幼机构要持续加强室内通风和清洁消毒，落 实晨午检和因病缺勤登记，发现暴发疫情要及时报告，引导师生做好手卫生和咳嗽礼仪。福利院、老人 院等人群聚集和场所密闭场所同样 ...

Core Viewpoint - The flu vaccine market in China is facing challenges due to low vaccination rates and price declines, but there is potential for recovery and growth driven by increased awareness and policy support [1][6][10]. Group 1: Industry Overview - The flu vaccine is a biological agent used to prevent influenza virus infections by stimulating the immune system to produce specific antibodies [1][4]. - In 2025, there were 5,675,403 reported cases of influenza in China, resulting in 25 deaths, highlighting the significant health and economic burden of the disease [4]. - The average vaccination rate in China from 2020 to 2024 remained below 4%, compared to over 50% in developed countries [6][10]. Group 2: Market Status - The total output value of flu vaccines in China is projected to decline to 7 billion yuan in 2024, with a potential recovery to 7.6 billion yuan in 2025 [6][10]. - The market is dominated by quadrivalent vaccines, which accounted for 71.4% of the output value in 2024, while trivalent vaccines made up 28.6% [7]. - The average bidding price for flu vaccines has decreased to 93 yuan per dose in 2024, with significant price reductions observed in government procurement [8][10]. Group 3: Competitive Landscape - Over 50 flu vaccines have been approved in China, with numerous manufacturers competing in a highly homogeneous market [9][10]. - Major players in the quadrivalent vaccine segment include Hualan Biological Engineering, Shanghai Institute of Biological Products, and Beijing Kexing [9][10]. - In 2024, Hualan Biological, Baike Biological, and Jindike reported revenues of 1.073 billion yuan, 141 million yuan, and 81 million yuan, respectively [10]. Group 4: Development Trends - The flu vaccine market in China has significant growth potential due to low vaccination rates among key populations, with a target vaccination rate of 75% for vulnerable groups [11]. - New technological advancements, such as mRNA vaccines, are emerging, with companies like Moderna and BioNTech making progress in clinical trials [11]. - The introduction of adjuvanted vaccines is also being explored, with several companies working on products that could fill gaps in the high-end market [11].

出品 | 36氪未来消费（微信ID：lslb168） 离你更近的消费创投一线。 整理 | 肖思佳 Busy Money "宁康瑞珠"完成超亿元A轮融资 36氪获悉，据舟渡资本消息，"宁康瑞珠"宣布完成超亿元人民币A轮融资。本轮融资由龙磐投资领投，峰瑞资本、阳光融汇资本跟投，舟渡资本担任独家 财务顾问。本轮融资将大幅加速拓展公司的技术平台，推进临床研究，布局差异化优势管线。 安澜动力完 成 千万元天使+轮融资 近日，安澜动力完成千万元天使+轮融资，这也是公司在半年内完成的第二轮融资。投资方：香港X科技基金（HKX）、清水湾二期基金、韧行投资。资 金用途：将重点用于产品功能样机的迭代研发与测试，团队人才完善。 安澜动力是一家专注于休闲船艇电动化与智能化研发的公司，致力于通过融合电动动力、网联和智能交互与创新设计，为亲水用户提供更省心、更便利、 更安全且环保的新一代电动智能摩托艇产品。在电动化方面，公司基于自主构建的船体三电耦合匹配平台，依托中国成熟的"三电"供应链，开发动力系 统解决方案。 江六筒宠物鲜食获2000万天使轮融资 近日，江六筒宠物鲜食完成2000万元天使轮融资。本轮融资将主要用于产品研发升级、产能扩 ...

Group 1 - Hema acknowledged a production issue with its strawberry cake, resulting in a salty taste, affecting approximately 60 sold units across 7 stores, and has initiated customer compensation and product adjustments [3] - Wanda Group has been reinstated for the execution of over 1.7 billion yuan, with the Gansu Mining District People's Court overseeing the case, amidst existing execution information totaling over 6.9 billion yuan [5] - PepsiCo announced plans to reduce its product variety in the U.S. market by nearly 20% by early next year, as part of cost-cutting measures to enhance operational efficiency [6] Group 2 - The International Monetary Fund (IMF) officially launched its Shanghai Regional Center to strengthen cooperation with the Asia-Pacific region, focusing on research and policy information sharing [13] - Faraday Future's board approved a five-year business plan targeting the production and sale of 400,000 to 500,000 vehicles, contingent on financing and strategic partnerships [14][15] - Paramount has proposed a cash acquisition offer of $30 per share for Warner Bros. Discovery, valuing the company at $108.4 billion [10]

Group 1 - Hema acknowledged issues with strawberry cakes sold, affecting approximately 60 units across 7 stores due to ingredient handling errors [2] - Wanda Group has a new enforcement order for over 1.7 billion yuan, with over 6.9 billion yuan in total enforcement amounts against the company [2] - The State Taxation Administration prohibits platform companies from shifting tax obligations to gig workers, ensuring they are not overcharged [3][9] Group 2 - PepsiCo plans to reduce its product variety in the U.S. market by nearly 20% by early next year, aiming to cut operational costs and enhance efficiency [5] - The price of three-valent flu vaccines has dropped to 5.5 yuan, attributed to intense competition and oversupply in the vaccine market [8] - Paramount has proposed a cash acquisition offer of $30 per share for Warner Bros. Discovery, valuing the company at $108.4 billion [7] Group 3 - Faraday Future's board approved a five-year plan to produce 400,000 to 500,000 vehicles, with the first batch of FX Super One vehicles set to roll off the production line [13] - The International Monetary Fund (IMF) has officially launched its Shanghai Regional Center to enhance cooperation with the Asia-Pacific region [12] - The U.S. government announced a $12 billion aid package for farmers affected by tariff policies, addressing the negative impact on agricultural markets [14]

Group 1 - The core point of the article highlights the significant price drop in various vaccines in the domestic market, with the three-valent flu vaccine priced at only 5.5 yuan, marking a new low for public flu vaccines [1] - The price of the two-valent HPV vaccine from Watson Bio has plummeted from 245 yuan per dose in 2022 to 27.5 yuan per dose in 2025, a decrease of nearly 90% [1] - The nine-valent HPV vaccine from Wantai Bio is priced at 499 yuan per dose, significantly lower than imported products, prompting the latter to engage in promotional activities to lower prices [1] Group 2 - The sharp decline in vaccine prices is expected to reduce public vaccination costs, theoretically improving vaccine accessibility and uptake [2] - Concerns have been raised regarding the potential impact of such low prices on public trust in vaccine quality, with fears that low-cost vaccines may compromise safety and effectiveness [2] - The public's skepticism may lead to a mindset of avoiding vaccinations altogether due to perceived risks associated with low-priced vaccines [2]

疫苗行业之所以陷入内卷式竞争，背后有多重原因，包括产品同质化竞争激烈、产能过剩问 题突出等。 疫苗市场正经历剧烈的价格震荡：一支三价流感疫苗价格低至5.5元，比一杯奶茶还便宜；而二价HPV 疫苗的价格，则是从几年前每支超过300元的高点骤降约九成，几乎只剩下"零头"…… 面对行业困境，近期中国疫苗行业协会发布了《关于反对"内卷式"竞争 促进疫苗及其相关生物制品行 业高质量发展的倡议》，明确提出"坚决抵制无序低价竞争，在招投标全流程中，严禁以低于成本的报 价参与竞标，切实保障产品与服务的质量标准"。 疫苗行业之所以陷入内卷式竞争，背后有多重原因。一方面，随着越来越多同类疫苗的上市，疫苗产品 同质化竞争激烈、产能过剩的问题日益突出。另一方面，受"疫苗犹豫"、新生儿数量下降等因素影响， 需求端增长乏力，供需的失衡进一步激化了价格战。 当前，疫苗市场无疑正处"寒冬"。但在中国疫苗行业协会市场专业委员会副主任委员刘沛诚看来，以流 感疫苗为代表的"内卷"，实质上是一种高度市场化的完全竞争状态，也是产业从分散走向集中过程中不 可避免的阶段。 "这种竞争不仅将淘汰劣质或竞争力较弱的企业，也为优质企业实现突破、提升市场地位创造 ...

Core Insights - The price war in the vaccine industry is driven by changes in supply and demand dynamics, leading to significant price reductions and financial losses for companies [2][10][15] Group 1: Price Trends - The price of a three-valent flu vaccine has dropped to 5.5 yuan, lower than the price of a cup of milk tea, indicating a drastic reduction in vaccine prices [3][7] - The price of the four-valent flu vaccine has decreased from 128 yuan to 88 yuan, with further reductions expected as competition intensifies [7][8] - HPV vaccines have also seen significant price drops, with the two-valent HPV vaccine priced at 27.5 yuan, down over 90% from previous prices [8] Group 2: Industry Response - The China Vaccine Industry Association issued an initiative to combat "involutionary" competition, urging members to avoid bidding below cost and maintain price stability [4][5] - The association's initiative aims to stabilize price expectations but may not address the underlying issue of overcapacity in the industry [3][10] Group 3: Market Dynamics - The vaccine market is experiencing overcapacity due to an influx of companies entering the sector, leading to intense competition and price wars [10][11] - Demand for vaccines is under pressure, with declining public trust in vaccines and a decrease in birth rates affecting the market for childhood vaccines [11][12] Group 4: Financial Impact - Vaccine companies have reported significant financial losses, with overall revenue for listed vaccine companies dropping by 60% and net profits declining by 113% in the first half of 2025 [12][14] - Major companies like Zhifei Biological and Wantai Biological have reported substantial revenue declines and net losses, reflecting the severe impact of the price war [12][14] Group 5: Future Outlook - Experts suggest that the industry may need to undergo a period of consolidation and restructuring, which could last five to ten years, to address the current challenges [15] - Companies are exploring international markets and differentiation strategies to navigate the competitive landscape, with some reporting significant increases in exports [15]

Core Viewpoint - The article discusses the ongoing price war in China's vaccine industry, driven by changes in supply and demand dynamics, leading to significant price reductions and financial losses for companies [4][15][22]. Group 1: Price War Dynamics - The price of a three-valent flu vaccine has dropped to 5.5 yuan, cheaper than a cup of milk tea, indicating a severe price competition in the vaccine market [5][11]. - The China Vaccine Industry Association has issued an initiative to combat "involution-style" competition, urging members to avoid bidding below cost and threatening penalties for violations [6][8][10]. - The price war has persisted for two years, with the association's initiative being the first formal stance against low-price competition, although it may not resolve the underlying issue of overcapacity [6][10][22]. Group 2: Supply and Demand Changes - The supply side is characterized by homogenization and overcapacity, with many companies entering the vaccine market, leading to intense competition and price wars [16][17]. - Demand is also under pressure, with declining public trust in vaccines and a decrease in vaccination rates, particularly for flu vaccines, which averaged below 4% in China from 2020 to 2023 [17][19]. - The shift in focus from childhood vaccines to adult vaccines due to declining birth rates has intensified competition in the adult vaccine market [17][19]. Group 3: Financial Impact on Companies - The financial repercussions of the price war are evident, with vaccine companies experiencing a 60% drop in revenue and a 113% decline in net profit in the first half of 2025 [19][20]. - Major companies like Zhifei Biological and Wantai Biological have reported significant losses, with Zhifei's revenue down 66.53% and net profit loss of 12.06 billion yuan [20][21]. - Despite some companies showing growth in sales, the overall trend indicates that increased revenue does not equate to increased profit due to drastic price reductions [21][22]. Group 4: Future Outlook and Strategies - Experts suggest that the industry is in a "deep cold moment," requiring a period of consolidation and restructuring that could last five to ten years [23]. - Companies are exploring two main strategies to navigate the competitive landscape: expanding into emerging markets and focusing on differentiated products to meet unmet clinical needs [24].